Show simple item record

dc.contributor.authorKohoutova, D
dc.contributor.authorWorku, D
dc.contributor.authorAziz, H
dc.contributor.authorTeare, J
dc.contributor.authorWeir, J
dc.contributor.authorLarkin, J
dc.coverage.spatialSwitzerland
dc.date.accessioned2022-08-26T09:56:40Z
dc.date.available2022-08-26T09:56:40Z
dc.date.issued2021-02-05
dc.identifierARTN 327
dc.identifiercells10020327
dc.identifier.citationCells, 2021, 10 (2), pp. 327 -en_US
dc.identifier.issn2073-4409
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5329
dc.identifier.eissn2073-4409
dc.identifier.eissn2073-4409
dc.identifier.doi10.3390/cells10020327
dc.identifier.doi10.3390/cells10020327
dc.description.abstractMalignant melanoma (MM) has become the fifth most frequent cancer in the UK. It is the most common carcinoma to metastasize to the gastrointestinal (GI) tract. MM particularly has an affinity to spread to the small bowel, which is followed by the involvement of the stomach and large intestine. Excellent endoscopic options including video capsule endoscopy and enteroscopy are available for a precise diagnosis of GI involvement by a metastatic MM. The complete surgical resection of GI metastatic MM in carefully selected patients not only provides symptom control, but has also been associated with an increase in overall survival. The approval of BRAF-targeted therapies and immune checkpoint inhibitors has transformed therapeutic approaches for patients with metastatic MM over the past decade. Currently, the overall survival of patients with advanced metastatic MM who have been treated with a combination of immunotherapeutic agents reaches 52% at five years. The role of surgery for patients with the metastatic involvement of the GI tract with MM is evolving in the era of effective systemic treatments.
dc.formatElectronic
dc.format.extent327 -
dc.languageeng
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.ispartofCells
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectBRAF/MEK inhibitors
dc.subjectgastrointestinal tract
dc.subjectimmunotherapy
dc.subjectmalignant melanoma
dc.subjectGastrointestinal Neoplasms
dc.subjectGastrointestinal Tract
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectMelanoma
dc.titleMalignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-01-29
dc.date.updated2022-08-26T09:56:08Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3390/cells10020327en_US
rioxxterms.licenseref.startdate2021-02-05
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/33562484
pubs.issue2
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.publication-statusPublished online
pubs.volume10
dc.contributor.icrauthorLarkin, James
icr.provenanceDeposited by Mr Arek Surman on 2022-08-26. Deposit type is initial. No. of files: 1. Files: Malignant Melanoma of the Gastrointestinal Tract Symptoms, Diagnosis, and Current Treatment Options. .pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/